Cogent Biosciences, Inc. - Common Stock, $0.001 Par Value (COGT)

Historical Holders from Q4 2020 to Q3 2025

Symbol
COGT on Nasdaq
CUSIP
19240Q201
Type / Class
Equity / Common Stock, $0.001 Par Value
Shares outstanding
117M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
136M
Holdings value
$973M
% of all portfolios
0.006%
Grand Portfolio weight change
+0%
Number of holders
176
Number of buys
106
Number of sells
-70
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cogent Biosciences, Inc. - Common Stock, $0.001 Par Value (COGT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% $70.6M 16.6M FMR LLC Dec 31, 2024
Fairmount Funds Management LLC 9.9% $73.5M 14.3M Fairmount Funds Management LLC Jul 10, 2025
Paradigm Biocapital Advisors LP 9.1% +15% $125M $16.8M 10.4M +15.5% Paradigm BioCapital Advisors LP Jun 30, 2025
Point72 Asset Management, L.P. 8.7% $42.5M 9.99M Point72 Asset Management, L.P. Dec 31, 2024
Flynn James E 6.49% $46.4M 9.05M Deerfield Mgmt, L.P. Jul 7, 2025
Commodore Capital LP 5.5% +18% $77.4M $13.8M 6.41M +21.6% Commodore Capital LP Jul 7, 2025
Venrock Healthcare Capital Partners II, L.P. 4.2% -26.7% $57.4M -$20.4M 4.76M -26.2% Venrock Healthcare Capital Partners II, L.P. Jun 30, 2025

Institutional Holders of Cogent Biosciences, Inc. - Common Stock, $0.001 Par Value (COGT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 639K $9.18M +$5.93M $14.36 3
2025 Q2 136M $973M +$19M $7.18 176
2025 Q1 133M $800M +$57.9M $5.99 182
2024 Q4 122M $949M -$21.7M $7.80 172
2024 Q3 122M $1.32B +$425K $10.80 160
2024 Q2 121M $1.02B +$107M $8.43 146
2024 Q1 109M $734M +$131M $6.72 143
2023 Q4 57.8K $340K +$150K $5.88 2
2023 Q3 90.9M $886M +$17.4M $9.75 134
2023 Q2 88.5M $1.05B +$159M $11.84 134
2023 Q1 75.1M $809M +$4.31M $10.79 132
2022 Q4 74.6M $863M -$1.88M $11.56 130
2022 Q3 73.7M $1.1B +$70.6M $14.92 127
2022 Q2 69.8M $629M +$207M $9.02 105
2022 Q1 44.1M $330M +$4.7M $7.49 80
2021 Q4 44.9M $385M +$45.2M $8.58 79
2021 Q3 36.8M $309M +$3.92M $8.41 70
2021 Q2 35M $283M +$1.29M $8.11 64
2021 Q1 34.5M $303M +$10.2M $8.78 66
2020 Q4 33.5M $376M +$318M $11.23 66